FibroGen, Inc.
FGEN
$10.48
$0.131.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 35.07% | -89.20% | 104.25% | 15.45% | -97.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.07% | -89.20% | 104.25% | 15.45% | -97.75% |
| Cost of Revenue | -81.69% | -83.70% | -97.97% | -58.73% | -67.88% |
| Gross Profit | 85.39% | 79.40% | 101.70% | 176.39% | 44.60% |
| SG&A Expenses | -52.66% | -51.50% | 283.57% | -31.36% | -52.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.56% | -76.48% | -79.60% | -51.04% | -64.19% |
| Operating Income | 74.88% | 69.92% | 94.79% | 103.49% | 47.29% |
| Income Before Tax | 70.92% | 65.81% | 90.89% | 73.13% | 46.11% |
| Income Tax Expenses | 67.26% | -71.43% | 101.14% | -85.71% | -19.57% |
| Earnings from Continuing Operations | 70.95% | 65.82% | 90.88% | 73.14% | 46.29% |
| Earnings from Discontinued Operations | -80.73% | 32.84% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 51.09% | 114.09% | 131.98% | 73.14% | 82.27% |
| EBIT | 74.88% | 69.92% | 94.79% | 103.49% | 47.29% |
| EBITDA | 74.93% | 70.09% | 95.01% | 105.19% | 46.53% |
| EPS Basic | 51.68% | 113.81% | 131.39% | 73.75% | 82.64% |
| Normalized Basic EPS | 72.10% | 66.73% | 93.70% | 102.84% | 47.24% |
| EPS Diluted | 51.68% | 113.81% | 131.39% | 73.75% | 82.64% |
| Normalized Diluted EPS | 72.10% | 66.73% | 93.70% | 102.84% | 47.24% |
| Average Basic Shares Outstanding | 1.23% | 1.99% | 3.63% | 2.31% | 2.14% |
| Average Diluted Shares Outstanding | 1.23% | 1.99% | 3.63% | 2.31% | 2.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |